Cargando…

Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series

OBJECTIVE: To assess the risk of solid organ transplant (SOT) rejection after vaccination with the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine Pandemrix. DESIGN: Self-controlled case series (SCCS) in the UK Clinical Practice Research Datalink (CPRD) and its linked component of the Hospi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohet, Catherine, Haguinet, François, Dos Santos, Gaël, Webb, Dave, Logie, John, LC Ferreira, Germano, Rosillon, Dominique, Shinde, Vivek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735133/ https://www.ncbi.nlm.nih.gov/pubmed/26823177 http://dx.doi.org/10.1136/bmjopen-2015-009264

Ejemplares similares

Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt
por: Dos Santos, Gaël, et al.
Publicado: (2017)

Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study
por: Nazareth, Irwin, et al.
Publicado: (2013)

Pandemrix™ and narcolepsy: A critical appraisal of the observational studies
por: Verstraeten, Thomas, et al.
Publicado: (2015)

Comparing the Immunogenicity of AS03-Adjuvanted 2009 Pandemic H1N1 Vaccine with Clinical Protection in Priority Risk Groups in England
por: Yung, Chee-Fu, et al.
Publicado: (2013)

Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England
por: Winstone, Anne Marie, et al.
Publicado: (2014)

Application of Probabilistic Multiple-Bias Analyses to a Cohort- and a Case-Control Study on the Association between Pandemrix(™)and Narcolepsy
por: Bollaerts, Kaatje, et al.
Publicado: (2016)

Short and Long-Term Safety of the 2009 AS03-Adjuvanted Pandemic Vaccine
por: De Serres, Gaston, et al.
Publicado: (2012)

Estimates of hospitalization attributable to influenza and RSV in the US during 1997–2009, by age and risk status
por: Matias, Gonçalo, et al.
Publicado: (2017)

Twin Peaks: A/H1N1 Pandemic Influenza Virus Infection and Vaccination in Norway, 2009–2010
por: Van Effelterre, Thierry, et al.
Publicado: (2016)

Estimates of mortality attributable to influenza and RSV in the United States during 1997–2009 by influenza type or subtype, age, cause of death, and risk status
por: Matias, Gonçalo, et al.
Publicado: (2014)

Risk of Narcolepsy Associated with Inactivated Adjuvanted (AS03) A/H1N1 (2009) Pandemic Influenza Vaccine in Quebec
por: Montplaisir, Jacques, et al.
Publicado: (2014)

Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 – A Comparison of Two Methods; Germany, 2009/10
por: Uphoff, Helmut, et al.
Publicado: (2011)

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials
por: Vaughn, David W, et al.
Publicado: (2014)

Importance of feasibility assessments before implementing non‐interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies
por: Willame, Corinne, et al.
Publicado: (2016)

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009
por: Skowronski, Danuta M, et al.
Publicado: (2011)

Multi-Centre Observational Study of Transplacental Transmission of Influenza Antibodies following Vaccination with AS03(A)-Adjuvanted H1N1 2009 Vaccine
por: Puleston, Richard, et al.
Publicado: (2013)

Reassessment of the risk of narcolepsy in children in England 8 years after receipt of the AS03-adjuvanted H1N1 pandemic vaccine: A case-coverage study
por: Stowe, Julia, et al.
Publicado: (2020)

Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infection in England and Scotland, 2009–2010
por: Calatayud, Laurence, et al.
Publicado: (2011)

Evaluation of immune response following one dose of an AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older
por: Ikematsu, Hideyuki, et al.
Publicado: (2012)

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
por: Launay, Odile, et al.
Publicado: (2013)

Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
por: Duval, Xavier, et al.
Publicado: (2012)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Age-Specific Effectiveness of an Oil-in-Water Adjuvanted Pandemic (H1N1) 2009 Vaccine Against Confirmed Infection in High Risk Groups in England
por: Andrews, Nick, et al.
Publicado: (2011)

Cortaillod 21.1.03 Techmeta 26.03.03 CMS SUPRA
Publicado: (2003)

Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012
por: Yanni, Emad A., et al.
Publicado: (2018)

Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study
por: Arnheim-Dahlström, Lisen, et al.
Publicado: (2012)

Donor-But Not Recipient-Derived Cells Produce Collagen-1 in Chronically Rejected Cardiac Allografts
por: Balam, Saidou, et al.
Publicado: (2022)

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
por: Goll, Johannes B., et al.
Publicado: (2022)

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland
por: Nohynek, Hanna, et al.
Publicado: (2012)

Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England
por: de Lusignan, Simon, et al.
Publicado: (2017)

AS03 stresses out macrophages: Commentary on ‘Activation of the endoplasmic reticulum stress sensor IRE1α by the vaccine adjuvant AS03 contributes to its immunostimulatory properties’
por: Orr, Mark T., et al.
Publicado: (2018)

Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea
por: Yu, Jianfeng, et al.
Publicado: (2022)

Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination
por: Galson, J. D., et al.
Publicado: (2016)

Analysis of Sera of Recipients with Allograft Rejection Indicates That Keratin 1 Is the Target of Anti-Endothelial Antibodies
por: Guo, Xuli, et al.
Publicado: (2017)

Serological report of pandemic (H1N1) 2009 infection among cats in Northeastern China in 2012-02 and 2013-03
por: Zhao, Fu-Rong, et al.
Publicado: (2014)

Erratum in: Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea
Publicado: (2022)

Acute Hepatic Allograft Rejection in Pediatric Recipients: Effective Factors
por: Dehghani, S. M., et al.
Publicado: (2018)

Acute Hepatic Allograft Rejection in Pediatric Recipients: Independent Factors
por: Dehghani, S. M., et al.
Publicado: (2017)

The Airway Microbiota Signatures of Infection and Rejection in Lung Transplant Recipients
por: Su, Jin, et al.
Publicado: (2022)

Endothelial failure and rejection in recipients of corneas from the same donor
por: Downward, Lewis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m5vvcnudl8va5f148fme9b48s6